Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
0-7-21 radiation therapy for the palliation of advanced cancer in dogsBateman, K.E. (University of Guelph, Guelph, Ontario, Canada.) ; Catton, P.A ; Pennock, P.W ; Kruth, S.AJournal of veterinary internal medicine, 1994-11, Vol.8 (6), p.394-399 [Periódico revisado por pares]Oxford, UK: Blackwell Publishing LtdTexto completo disponível |
|
2 |
Material Type: Artigo
|
0-7-21 radiation therapy for the treatment of canine oral melanomaBateman, K.E. (University of Guelph, Guelph, Ontario) ; Catton, P.A ; Pennock, P.W ; Kruth, S.AJournal of veterinary internal medicine, 1994-07, Vol.8 (4), p.267-272 [Periódico revisado por pares]Oxford, UK: Blackwell Publishing LtdTexto completo disponível |
|
3 |
Material Type: Artigo
|
0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis : Results of a randomized, open-label, observer-blinded studyORTONNE, Jean-Paul ; VAN DE KERKHOF, Peter C. M ; PRINZ, Jorg C ; BIEBER, Thomas ; LAHFA, Morad ; RUBINS, Andris ; WOZEL, Gottfried ; LORETTE, GerardActa dermato-venereologica, 2006-01, Vol.86 (1), p.29-33 [Periódico revisado por pares]Uppsala: Acta dermato-venereologicaTexto completo disponível |
|
4 |
Material Type: Artigo
|
0.5% levobupivacaine versus 0.5% ropivacaine: Are they different in ultrasound-guided sciatic block?Pham Dang, Charles ; Langlois, Cécile ; Lambert, Chantal ; Nguyen, Jean-Michel ; Asehnoune, Karim ; Lejus, CorinneSaudi journal of anaesthesia, 2015-01, Vol.9 (1), p.3-8 [Periódico revisado por pares]India: Medknow Publications and Media Pvt. LtdTexto completo disponível |
|
5 |
Material Type: Artigo
|
0.5% levobupivacaine versus 0.5% ropivacaine: Are they different in ultrasound-guided sciatic block?: ErratumSaudi journal of anaesthesia, 2015-04, Vol.9 (2), p.235-235 [Periódico revisado por pares]Riyadh: Medknow Publications and Media Pvt. LtdTexto completo disponível |
|
6 |
Material Type: Artigo
|
0.5% Proparacain hydrochloride for clear corneal phacoemulsification in patients with co-morbid conditionsJoshi, RajeshIndian journal of ophthalmology, 2014-11, Vol.62 (11), p.1101-1101 [Periódico revisado por pares]India: Medknow PublicationsTexto completo disponível |
|
7 |
Material Type: Artigo
|
0.9% saline V/S Ringer's lactate for fluid resuscitation in adult sepsis patients in emergency medical services: An open-label randomized controlled trialGolla, Rithvik ; Kumar, Susheel ; Dhibhar, Deba Prasad ; Bhalla, Ashish ; Sharma, NavneetHong Kong journal of emergency medicine, 2022-09, Vol.29 (5), p.271-280 [Periódico revisado por pares]Hong Kong: SAGE PublicationsTexto completo disponível |
|
8 |
Material Type: Artigo
|
1-[1-(2-Benzo[ b]thiopheneyl)cyclohexyl]piperidine hydrochloride (BTCP) yields two active primary metabolites in vivo : Identification and quantification of BTCP primary metabolites in mice plasma, urine, and brain and their affinity for the neuronal dopamine transporterDeleuze-Masquefa, Carine ; Michaud-Dutreilh, Martine ; Vignon, Jacques ; Kamenka, Jean-MarcEuropean journal of pharmaceutical sciences, 2000-02, Vol.9 (4), p.345-354 [Periódico revisado por pares]Shannon: Elsevier B.VTexto completo disponível |
|
9 |
Material Type: Artigo
|
1,1-Bis (3′-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis modelAndey, Terrick ; Patel, Apurva ; Jackson, Tanise ; Safe, Stephen ; Singh, MandipEuropean journal of pharmaceutical sciences, 2013-10, Vol.50 (2), p.227-241 [Periódico revisado por pares]Netherlands: Elsevier B.VTexto completo disponível |
|
10 |
Material Type: Artigo
|
1,12-cyclic apelin-12 ameliorates Ang II and Apelin-13-induced cardiac hypertrophy by reducing mitochondrial oxidative damageOuyang, Xueqian ; Chen, Wei ; Peng, Guolong ; Liu, Huimei ; Fan, Sisi ; Li, Qin ; Wang, Liwen ; Chen, Linxi ; Li, LanfangChinese medical journal, 2024-03, Vol.137 (6), p.749-751 [Periódico revisado por pares]China: Lippincott Williams & Wilkins Ovid TechnologiesTexto completo disponível |